Search

Your search keyword '"GÜL, Ahmet"' showing total 1,222 results
Start Over Author "GÜL, Ahmet"
1,222 results on '"GÜL, Ahmet"'

8. Tocilizumab treatment in severe COVID-19: a multicenter retrospective study with matched controls

Author

Mert, Ali, Vahaboğlu, Haluk, Arslan, Ferhat, Batirel, Ayşe, Saraçoğlu, Kemal Tolga, Bastug, Aliye, Çağatay, Atahan, Irmak, İlim, Dizman, Gülçin Telli, Ertenli, İhsan, Altunal, Lütfiye Nilsun, Sengel, Buket Ertürk, Bayram, Mehmet, Omma, Ahmet, Amikishiyev, Shirkhan, Aypak, Adalet, Bes, Cemal, Bolukçu, Sibel, Içten, Sacit, Topeli, Arzu, Bektaş, Murat, Arslan, Birsen Yiğit, Öztürk, Sinan, Çomoğlu, Şenol, Aydin, Selda, Küçükşahin, Orhan, Içaçan, Ozan Cemal, Ince, Burak, Aghamuradov, Sarvan, Mutlu, Melek Yalçin, Şimşek, Funda, Emre, Salih, Ustun, Cemal, Ergen, Pinar, Aydin, Özlem, Koç, Meliha Meriç, Sevindik, Ömür Gökmen, Odabaşı, Zekaver, Korten, Volkan, Bodur, Hurrem, Güner, Rahmet, Ünal, Serhat, Kocak, Mehmet, and Gül, Ahmet

Published
2022
Full Text
View/download PDF

11. Budd–Chiari syndrome in Behçet’s disease: a retrospective multicenter study

Author

Akyol, Lütfi, Toz, Bahtiyar, Bayındır, Özün, Zengin, Orhan, Cansu, DöndüÜsküdar, Yiğit, Murat, Çetin, Gözde Yıldırım, Omma, Ahmet, Erden, Abdulsamet, Küçükşahin, Orhan, Altuner, Mehmet Şakir, Çorba, BurçinŞeyda, Ünal, Ali Uğur, Küçük, Hamit, Küçük, Adem, Balkarli, Ayşe, Gönüllü, Emel, Tufan, Ayşe Nur, Bakırcı, Sibel, Öner, Sibel Yılmaz, Balcı, Mehmet Ali, Kobak, Şenol, Yazıcı, Ayten, Özgen, Metin, Şahin, Ali, Koca, Süleyman Serdar, Erer, Burak, Gül, Ahmet, Aksu, Kenan, Keser, Gökhan, Onat, Ahmet Mesut, Kısacık, Bünyamin, Kaşifoğlu, Timuçin, Çefle, Ayşe, Kalyoncu, Umut, and Sayarlıoğlu, Mehmet

Published
2022
Full Text
View/download PDF

15. Common genetic susceptibility loci link PFAPA syndrome, Behçet’s disease, and recurrent aphthous stomatitis

Author

The Genomic Ascertainment Cohort, Manthiram, Kalpana, Preite, Silvia, Dedeoglu, Fatma, Demir, Selcan, Ozen, Seza, Edwards, Kathryn M., Lapidus, Sivia, Katz, Alexander E., Feder, Henry M., Lawton, Maranda, Licameli, Greg R., Wright, Peter F., Le, Julie, Barron, Karyl S., Ombrello, Amanda K., Barham, Beverly, Romeo, Tina, Jones, Anne, Srinivasalu, Hemalatha, Mudd, Pamela A., DeBiasi, Roberta L., Gül, Ahmet, Marshall, Gary S., Jones, Olcay Y., Chandrasekharappa, Settara C., Stepanovskiy, Yuriy, Ferguson, Polly J., Schwartzberg, Pamela L., Remmers, Elaine F., and Kastner, Daniel L.

Published
2020

19. Behçet Disease

Author

Gül, Ahmet, Hashkes, Philip J., editor, Laxer, Ronald M., editor, and Simon, Anna, editor

Published
2019
Full Text
View/download PDF

27. Ancient familial Mediterranean fever mutations in human pyrin and resistance to Yersinia pestis

Author

Park, Yong Hwan, Remmers, Elaine F., Lee, Wonyong, Ombrello, Amanda K., Chung, Lawton K., Shilei, Zhao, Stone, Deborah L., Ivanov, Maya I., Loeven, Nicole A., Barron, Karyl S., Hoffmann, Patrycja, Nehrebecky, Michele, Akkaya-Ulum, Yeliz Z., Sag, Erdal, Balci-Peynircioglu, Banu, Aksentijevich, Ivona, Gül, Ahmet, Rotimi, Charles N., Chen, Hua, Bliska, James B., Ozen, Seza, Kastner, Daniel L., Shriner, Daniel, and Chae, Jae Jin

Published
2020
Full Text
View/download PDF

29. Behçet Disease

Author

Gül, Ahmet, Ragab, Gaafar, editor, Atkinson, T. Prescott, editor, and Stoll, Matthew L., editor

Published
2018
Full Text
View/download PDF

32. Serum and urine interferon-inducible protein 10, galectin-9, and SIGLEC-1 as biomarkers of disease activity in systemic lupus erythematosus.

Author

MİRİOĞLU, Şafak, ÇINAR, Suzan, ULUDAĞ, Ömer, GÜREL, Erdem, VARELCİ, Sibel, ÖZLÜK, Yasemin, KILIÇASLAN, Işın, YALÇINKAYA, Yasemin, YAZICI, Halil, GÜL, Ahmet, İNANÇ, Murat, and ESEN, Bahar ARTIM

Subjects
SYSTEMIC lupus erythematosus, BIOMARKERS, URINE
Abstract

Background/aim: In this prospective study, we aimed to investigate the association of serum (s) and urine (u) IP-10, galectin-9, and SIGLEC-1 with disease activity in patients with systemic lupus erythematosus (SLE). Materials and methods: Sixty-three patients with active SLE (31 renal, 32 extrarenal) were included. Thirty patients with inactive SLE (15 renal, 15 extrarenal), 17 with renal active AAV, and 32 healthy volunteers were selected as control groups. Serum and urine IP-10, galectin-9, and SIGLEC-1 were tested using ELISA. Results: Levels of sIP-10 (p = 0.046), uIP-10 (p < 0.001), sGalectin-9 (p = 0.03), and uSIGLEC-1 (p = 0.006) were significantly higher in active SLE group compared to the inactive SLE; however, no differences were detected in the comparison of uGalectin-9 (p = 0.18) and sSIGLEC-1 (p = 0.69) between two groups. None of the biomarkers discriminated patients with active renal SLE from active extrarenal SLE. ROC analyses revealed an AUC of 0.63 (0.52--0.73) for sIP-10, 0.78 (0.68--0.86) for uIP-10, 0.64 (0.53--0.74) for sGalectin-9, and 0.68 (0.57--0.77) for uSIGLEC-1 in discriminating disease activity in SLE, which did not outperform C3 (0.75, 0.64--0.84) and C4 (0.72, 0.61--0.82). sIP-10 (p = 0.001), uIP-10 (p = 0.042), and uGalectin-9 (p = 0.009) were significantly increased in patients with active renal SLE compared to active renal AAV. sGalectin-9 (p < 0.001) and sIP-10 levels (p = 0.06) were decreased after 8 (5--22.5) months of treatment. Conclusion: sIP-10, uIP-10, sGalectin-9, and uSIGLEC-1 reflect global disease activity in SLE but do not outperform C3 and C4. sIP-10 and uIP-10 may be specific for active SLE compared to active AAV. sIP-10 and sGalectin-9 might be valuable in monitoring response after treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. Analysis of 5-year hospitalization data of patients with systemic lupus erythematosus: Damage is a risk factor for frequent and longer stays.

Author

Çetin, Çiğdem, Can, Melodi Gizem, Öztaşkın, Sinem, Yalçınkaya, Yasemin, Gül, Ahmet, İnanç, Murat, and Artım Esen, Bahar

Subjects
SYSTEMIC lupus erythematosus, HOSPITAL care, HEART valves, INTENSIVE care units, ANTIPHOSPHOLIPID syndrome, PULMONARY hypertension
Abstract

Objective: The annual hospitalization rate of patients with systemic lupus erythematosus (SLE) is approximately 10%, and hospitalizations are responsible for most of the healthcare expenses. Herein, we analyzed 5-year hospitalization data of SLE patients and determined factors leading to hospitalization. Methods: Clinical, laboratory, and hospitalization data of SLE patients admitted to our rheumatology clinic in 2015–2020 were retrieved from our SLE database and analyzed. SLICC SLE damage index (SDI) and disease activity at admission (SLEDAI-2K) were determined. Results: Among 161 hospitalized patients, 86% were females. Total rheumatologic hospitalization number was 298, and 38% of the patients were hospitalized more than once (1.85 ± 1.56). The mean hospitalization duration covering all stays for each patient was 25 ± 26.5 days. Active disease, infection, and damage-related complications were first three causes of hospitalization. Compared to patients hospitalized for active disease or damage, patients hospitalized for infection had a significantly higher number of readmissions (p <.05) and their total hospital stay was longer (p <.01). The frequency of patients with damage and the mean SDI score was significantly lower in the active disease group (68%, 1.93 ± 2.05) than hospitalizations for infection (90%, 2.68 ± 1.63) and damage-related causes (96%, 3.04 ± 1.65) (p <.05). The mean SDI score and duration (r = 0.551, p <.001) and the number of hospitalizations (r = 0.393, p <.001) were positively correlated. The mean disease activity scores of patients hospitalized for active disease, infection, and damage-related reasons were 11.03 ± 6.08, 3.21 ± 2.80, and 2.96 ± 3.32, respectively (p <.001). Renal active disease was the most common (44%), followed by hematological (34.8%), articular (21.7%), and mucocutaneous (21%) activity. Ten percent of the patients all of whom had damage were admitted to intensive care unit (ICU). Total hospitalization duration, mean SDI, antiphospholipid syndrome, lupus anticoagulant, thrombocytopenia, serositis, pulmonary hypertension, history of alveolar hemorrhage, and cardiac valve involvement were associated with ICU admission (p <.05 for all). Conclusion: Disease activity, infections, and damage are the leading causes of hospitalization in SLE patients. Damage prolongs hospital stay and increases hospitalization rate and ICU need. Tight control of disease activity with rational use of immunosuppressive treatment is important to reduce damage and hospitalizations. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

46. Intracranial granuloma in a patient with granulomatosis with polyangiitis under rituximab maintenance: A case report.

Author

Ince, Burak, Eroğlu, Elif, Barburoğlu, Mehmet, Yalçinkaya, Yasemin, Artim‐Esen, Bahar, Gül, Ahmet, and Inanç, Murat

Subjects
GRANULOMATOSIS with polyangiitis, ANTINEUTROPHIL cytoplasmic antibodies, GRANULOMA, DISEASE remission, RITUXIMAB, POLYARTERITIS nodosa
Abstract

Background: Rituximab (RTX) is being used for both induction and maintenance of anti‐neutrophil cytoplasmic antibody (ANCA) ‐associated vasculitis. However, the efficacy of RTX for the granulomatous findings of granulomatosis with polyangiitis (GPA) has not been demonstrated as clearly as its vasculitic manifestations. Case summary: A 46‐year‐old man was diagnosed in 2019 with GPA with constitutional symptoms, bilateral mastoiditis, prostatic necrosis, nodules in both lungs, pauci‐immune necrotizing glomerulonephritis and high level of PR3‐ANCA. He reached clinical remission after induction with high‐dose corticosteroids and intravenous cyclophosphamide pulses at the 3rd month. Two months following the second cycle of RTX as maintenance, he developed multiple cranial mass lesions, and excisional biopsy revealed necrotizing vasculitis with granuloma formation. Remission was achieved with long‐term high‐dose corticosteroid therapy after surgical excision. Conclusion: We observed a relapse of GPA with intracranial granulomatous lesions in a patient under RTX maintenance. Limited efficacy of RTX should be considered for mainly granulomatous manifestations in patients with GPA. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

49. Utility of positron emission tomography as a new tool for muscle involvement in patients with idiopathic inflammatory myositis: a controlled study

Author

Bektaş, Murat, primary, Işık, Emine Göknur, additional, Oğuz, Emin, additional, Kemik, Fatih, additional, Abbasgholizadeh, Anna, additional, İnce, Burak, additional, Özkan, Zeynep Gözde, additional, Yalçınkaya, Yasemin, additional, Artım-Esen, Bahar, additional, Gül, Ahmet, additional, and İnanç, Murat, additional

Published
2023
Full Text
View/download PDF

50. Criteria for Hyperinflammation Developing in COVID ‐19: Analysis of 2 Cohorts From Different Periods of the Pandemic

Author

Amikishiyev, Shirkhan, primary, Gunver, M. Guven, additional, Bektas, Murat, additional, Aghamuradov, Sarvan, additional, Ince, Burak, additional, Koca, Nevzat, additional, Torun, Ege Sinan, additional, Aliyeva, Numune, additional, Sari, Selma, additional, Cetin, Cigdem, additional, Yalcin‐Dulundu, Banu C., additional, Deniz, Rabia, additional, Kemik, Fatih, additional, Agargun, Besim Fazil, additional, Gulseren, Ubeyde Ayse, additional, Besisik, Beliz, additional, Alkan, Onur, additional, Bagriacik, Ceren, additional, Tor, Yavuz B., additional, Senkal, Naci, additional, Catma, Yunus, additional, Durak, Gorkem, additional, Mese, Sevim, additional, Agacfidan, Ali, additional, Kose, Murat, additional, Erelel, Mustafa, additional, Cagatay, A. Atahan, additional, Simsek‐Yavuz, Serap, additional, Kalayoglu‐Besisik, Sevgi, additional, Esen, Figen, additional, and Gül, Ahmet, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results